Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: Focus on irbesartan/ hydrochlorothiazide

International Journal of Clinical Practice

Volumn 61, Issue 12, 2007, Pages 2093-2102

  Flack, J M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ADD ON THERAPY; ALBUMINURIA; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; LIPID BLOOD LEVEL; LOW DRUG DOSE; MEDICAL SOCIETY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES;

EID: 35948975642     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01577.x     Document Type: Review

References (61)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000. JAMA 2003 290 : 199 206.
2. National Institutes of Health, National Heart, Lung, and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No. 04-5230, August 2004.
3. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 363 : 2022 31.
4. Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004 363 : 2049 51.
5. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001 6 : 63 72.
6. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997 95 : 1085 90 RW, Clover K. Compliance in the treatment of hypertension: a need for action. Am J Hypertens 1995 8 : S82 88.
7. Hansson L. Why don't you do as I tell you? Compliance and antihypertensive regimens. Int J Clin Pract 2002 56 : 191 6.
8. Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995 91 : 69 706.
9. Flack JM, Saunders E, Gradman A et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African-Americans with mild to moderate hypertension. Clin Ther 2001 23 : 1193 208.
10. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998 20 : 671 81.
11. Weir MR, Prisant LM, Papedemetriou V et al. Correlation of prior antihypertensive therapy, current therapy (amlopidine, bisoprolol/HCTZ, enalapril), adverse events and blood pressure reduction with changes in quality of life. Am J Hypertens 1995 4 : 132A.
12. Black HR, Elliott WJ, Neaton JD et al. for the CONVINCE Research Group. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2002 37 : 12 8.
13. Cushman WC, Ford CE, Cutler JA et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002 4 : 393 404.
14. Hanssen L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 351 : 1755 62.
15. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans. Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003 163 : 525 41.
16. European Society of Hypertension Practice. Practice Guidelines for Primary Care Physicians: 2003 ESH/ESC Hypertension Guidelines. J Hypertens 2003 21 : 1011 53.
17. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005 366 : 895 906.
18. Saito I, Saruta T. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. Hypertens Res 2006 29 : 789 96.
19. Zanchetti A, Parati G, Malacco E. Zofenopril plus hydrochlorothiazide: combination therapy for the treatment of mild to moderate hypertension. Drugs 2006 66 : 1107 15.
20. Chrysant SG, Chrysant C, Trus J, Hitchcock A. Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide. Am J Hypertens 1989 2 : 537 41.
21. Frei M, Kuster L, Gardosch Krosigk von Koch HF, Kuppers H. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994 24 (Suppl. 1 S25 8.
22. Lindholm LH, Ibsen H, Dahlöf B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002 359 : 1004 10.
23. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 345 : 861 9.
24. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 345 : 870 8.
25. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 345 : 851 60.
26. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 345 : 1667 75.
27. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 349 : 1893 906.
28. Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004 44 : 1175 80.
29. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction the CHARM-Preserved Trial. Lancet 2003 362 : 777 81.
30. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003 362 : 772 6.
31. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the Charm-Added trial. Lancet 2003 362 : 767 71.
32. Kjeldsen SE, Julius S, Mancia G et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006 24 : 1405 12.
33. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005 45 : 712 9.
34. Conlin PR, Spence JD, Williams B et al. Angiotensin II antagonists for hypertension: are there differences in efficacy Am J Hypertens 2000 13 : 418 26.
35. Kjeldsen SE, Os I, Høieggen A et al. Fixed dose combinations in the management of hypertension. Defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005 5 : 17 22.
36. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a North of Sweden efficacy evaluation (ALPINE) study. J Hypertens 2003 21 : 1563 74.
37. Hoiggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004 65 : 1041 9.
38. Malacco E, Sanronastaso M, Varì NA et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the blood pressure reduction and tolerability of valsartan in comparison with lisinopril (PREVAIL) study. Clin Ther 2004 26 : 855 65.
39. López-Sendón J, Swedberg K, McMurray J et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Taskforce on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004 25 : 1454 70.
40. Bakris GL, Siomos M, Richardson D et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K study. Kidney Int 2000 58 : 2084 92.
41. Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs 2002 62 : 787 816.
42. Wellington K, Faulds DM. Valsartan hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place and place in the management of hypertension. Drugs 2002 62 : 1983 2005.
43. Ruilope LM, Malacco E, Khder Y et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005 27 : 578 87.
44. Kochar M, Guthrie R, Triscari J et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999 12 : 797 805.
45. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001 23 : 833 50.
46. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxmil and hydrochlorothiazide. Am J Hypertens 2004 17 : 252 9.
47. Pool JL, Glazer R, Weinberger M et al. Comparison of valsartan/ hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007 29 : 61 73.
48. Rosenstock J, Rossi L, Lin CS et al. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther 1998 23 : 433 40.
49. Raskin P, Guthrie R, Flack J et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999 13 : 683 7.
50. Mancia G, Korlipara K, van Rossum P et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002 7 : 135 42.
51. Bobrie G, Delonca J, Moulin C et al. for the COSIMA Investigators. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005 18 : 1482 8.
52. White WB, Punzi HA, Murwin D et al. Effects of the angiotensin II receptor blockers telmisartan vs. valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. J Clin Hypertens (Greenwich) 2006 8 : 626 33.
53. Fogari R, Zoppi A, Mugellini A et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006 23 : 680 95.
54. Oparil S, Aurup P, Snavely D, Goldberg A. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol 2001 87 : 721 6.
55. Bonner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr Med Res Opin 2004 20 : 597 602.
56. Neutel JM, Smith DH, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract 1999 53 : 175 8.
57. Sega R. Efficacy and safety of eprosartan in severe hypertension. Blood Press 1999 8 : 114 21.
58. Coca A, Calvo C, Sobrino J et al. Once-daily fixed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther 2003 25 : 2849 64.
59. Neutel JM, Saunders E, Bakris GL et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005 7 : 578 86.
60. Neutel JM, Franklin SS, Oparil S et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) 2006 8 : 850 7.
61. Rossing K, Mischak H, Parving HH, et al. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005 68 : 193 205.